These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

80 related items for PubMed ID: 8745532

  • 1. Construction, expression and characterization of tissue-type plasminogen activator mutants.
    Liu S, Huang P, Huang C.
    Sci China B; 1995 Nov; 38(11):1341-8. PubMed ID: 8745532
    [Abstract] [Full Text] [Related]

  • 2. Construction, expression and the characterization of t-PA mutants with increased plasma half-life and resistance to inhibition by PAI-1.
    Liu S, Huang P, Huang C.
    Chin J Biotechnol; 1995 Nov; 11(1):17-25. PubMed ID: 7548767
    [Abstract] [Full Text] [Related]

  • 3. Characterization of human tissue-type plasminogen activator variants with amino acid mutations in the kringle 1 domain.
    Ikenaka Y, Yajima K, Yahara H, Maruyama H, Matsumoto K, Okada K, Ueshima S, Matsuo O.
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):381-7. PubMed ID: 1330023
    [Abstract] [Full Text] [Related]

  • 4. Plasminogen activator inhibitor 1 contains a cryptic high affinity receptor binding site that is exposed upon complex formation with tissue-type plasminogen activator.
    Horn IR, van den Berg BM, Moestrup SK, Pannekoek H, van Zonneveld AJ.
    Thromb Haemost; 1998 Nov; 80(5):822-8. PubMed ID: 9843178
    [Abstract] [Full Text] [Related]

  • 5. Expression and characterization of recombinant porcine plasminogen activator inhibitor-1.
    Bijnens AP, Knockaert I, Cousin E, Kruithof EK, Declerck PJ.
    Thromb Haemost; 1997 Feb; 77(2):350-6. PubMed ID: 9157595
    [Abstract] [Full Text] [Related]

  • 6. Kinetic characterization of tissue-type plasminogen activator (t-PA) and t-PA deletion mutants.
    de Vries C, Veerman H, Nesheim ME, Pannekoek H.
    Thromb Haemost; 1991 Mar 04; 65(3):280-5. PubMed ID: 1904654
    [Abstract] [Full Text] [Related]

  • 7. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis.
    Björquist P, Ehnebom J, Inghardt T, Hansson L, Lindberg M, Linschoten M, Strömqvist M, Deinum J.
    Biochemistry; 1998 Feb 03; 37(5):1227-34. PubMed ID: 9477948
    [Abstract] [Full Text] [Related]

  • 8. Inhibitor-resistant tissue-type plasminogen activator: an improved thrombolytic agent in vitro.
    Shohet RV, Spitzer S, Madison EL, Bassel-Duby R, Gething MJ, Sambrook JF.
    Thromb Haemost; 1994 Jan 03; 71(1):124-8. PubMed ID: 8165630
    [Abstract] [Full Text] [Related]

  • 9. The variable region-1 from tissue-type plasminogen activator confers specificity for plasminogen activator inhibitor-1 to thrombin by facilitating catalysis: release of a kinetic block by a heterologous protein surface loop.
    Dekker RJ, Eichinger A, Stoop AA, Bode W, Pannekoek H, Horrevoets AJ.
    J Mol Biol; 1999 Oct 29; 293(3):613-27. PubMed ID: 10543954
    [Abstract] [Full Text] [Related]

  • 10. Different structural requirements for plasminogen activator inhibitor 1 (PAI-1) during latency transition and proteinase inhibition as evidenced by phage-displayed hypermutated PAI-1 libraries.
    Stoop AA, Eldering E, Dafforn TR, Read RJ, Pannekoek H.
    J Mol Biol; 2001 Jan 26; 305(4):773-83. PubMed ID: 11162091
    [Abstract] [Full Text] [Related]

  • 11. Construction and characterization of a t-PA mutant for use in ATTEMPTS: a drug delivery system for achieving targeted thrombolysis.
    Yang VC, Naik SS, Song H, Dombkowski AA, Crippen G, Liang JF.
    J Control Release; 2005 Dec 10; 110(1):164-76. PubMed ID: 16260060
    [Abstract] [Full Text] [Related]

  • 12. [Expression and activity of tissue-type plasminogen activator mutant reteplase with deletion of PAI-1 binding sites].
    Zhu MC, Zhan Z, Wang YJ, Liu CG, Shi Y, Cai Q.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep 10; 21(5):565-9. PubMed ID: 16143058
    [Abstract] [Full Text] [Related]

  • 13. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
    Paoni NF, Keyt BA, Refino CJ, Chow AM, Nguyen HV, Berleau LT, Badillo J, Peña LC, Brady K, Wurm FM.
    Thromb Haemost; 1993 Aug 02; 70(2):307-12. PubMed ID: 8236140
    [Abstract] [Full Text] [Related]

  • 14. A novel variant of t-PA resistant to plasminogen activator inhibitor-1; expression in CHO cells based on in silico experiments.
    Davami F, Sardari S, Majidzadeh-A K, Hemayatkar M, Barkhordari F, Enayati S, Adeli A, Mahboudi F.
    BMB Rep; 2011 Jan 02; 44(1):34-9. PubMed ID: 21266104
    [Abstract] [Full Text] [Related]

  • 15. Effect of Tisseel on expression of tissue plasminogen activator and plasminogen activator inhibitor-1.
    Diamond MP, Kruger M, Saed GM.
    Fertil Steril; 2004 Jun 02; 81(6):1657-64. PubMed ID: 15193491
    [Abstract] [Full Text] [Related]

  • 16. 19F NMR studies of plasminogen activator inhibitor-1.
    Abbott GL, Blouse GE, Perron MJ, Shore JD, Luck LA, Szabo AG.
    Biochemistry; 2004 Feb 17; 43(6):1507-19. PubMed ID: 14769027
    [Abstract] [Full Text] [Related]

  • 17. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J, Aleem AM, Selman SH, Skrzypczak-Jankun E, Lysiak-Szydlowska W, Grafos N, Fryer HJ, Greenfield RS.
    Int J Mol Med; 2007 Nov 17; 20(5):683-7. PubMed ID: 17912461
    [Abstract] [Full Text] [Related]

  • 18. Deletion of residues K296-G302 from the slowly-cleared tissue-type plasminogen activator t-PA del (G) leads to partial loss of plasminogen activating activity.
    Dodd I, Browne MJ, Chapman CG, Cronk D, Hastwell C, Wilson S, Robinson JH.
    Biologicals; 1993 Sep 17; 21(3):269-74. PubMed ID: 8117440
    [Abstract] [Full Text] [Related]

  • 19. Elucidation of the structural basis for the slow reactivity of thrombin with plasminogen activator inhibitor-1.
    Rezaie AR.
    Biochemistry; 1998 Sep 22; 37(38):13138-42. PubMed ID: 9748320
    [Abstract] [Full Text] [Related]

  • 20. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S, Larsen JV, Pedersen KE, Petersen HH, Egelund R, Christensen A, Jensen JK, Gliemann J, Andreasen PA.
    FEBS J; 2006 Nov 22; 273(22):5143-59. PubMed ID: 17042782
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.